Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

The Lancet

Volumn 384, Issue 9958, 2014, Pages 1942-1951

  Raffi, François ^a   Babiker, Abdel G ^b   Richert, Laura ^c   Molina, Jean Michel ^d   George, Elizabeth C ^b   Antinori, Andrea ^e   Arribas, Jose R ^f   Grarup, Jesper ^g   Hudson, Fleur ^b   Schwimmer, Christine ^c   Saillard, Juliette ^h   Wallet, Cédrick ^c   Jansson, Per O ^g   Allavena, Clotilde ^a   Van Leeuwen, Remko ⁱ   Delfraissy, Jean François ^j   Vella, Stefano ^k   Chêne, Geneviève ^c   Pozniak, Anton ^l  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h ANR   (France)

ⁱ ACADEMIC MEDICAL CENTER   (Netherlands)

^j BICÊTRE HOSPITAL   (France)

^k ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^l CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; RALTEGRAVIR; RITONAVIR; VIRUS RNA; 2 PYRROLIDONE DERIVATIVE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHONIC ACID DERIVATIVE; SULFONAMIDE; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; HIV INFECTIONS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADENINE; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PYRROLIDINONES; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84919458152     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61170-3     Document Type: Article

References (33)

1. European AIDS Clinical Society Guidelines for treatment of HIV-infected adults in Europe http://eacsociety.org/Portals/0/140601-EACS%20EN7.02.pdf (accessed July 10, 2014).
2. TT Brown Challenges in the management of osteoporosis and vitamin D deficiency in HIV infection Topics Antivir Med 21 2013 115 118
3. AM Hall, BM Hendry, D Nitsch, JO Connolly Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence Am J Kidney Dis 57 2011 773 780
4. GA McComsey, P Tebas, E Shane et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers Clin Infect Dis 51 2010 937 946
5. C Orkin, E DeJesus, H Khanlou et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial HIV Med 14 2013 49 59
6. Landovitz RJ, Ribaudo HJ, Ofotokun I, et al. Efficacy and tolerability of atazanavir, raltegravir, or darunavir with FTC/tenofovir: ACTG 5257. 21st Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; March 3-6, 2014. Abstr 85.
7. JL Lennox, E DeJesus, A Lazzarin et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374 2009 796 806
8. JM Murray, S Emery, AD Kelleher et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase AIDS 21 2007 2315 2321
9. A Jackson, V Watson, D Back et al. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals J Acquir Immune Defic Syndr 58 2011 450 457
10. VA Johnson, F Brun-Vezinet, B Clotet et al. Update of drug resistance mutations in HIV-1: December 2009 Top HIV Med 17 2009 138 145
11. European AIDS Clinical Society Clinical management and treatment of HIV infected adults in Europe, version 5 2009 European AIDS Clinical Society/EACS Brussels
12. R Ortiz, E Dejesus, H Khanlou et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 AIDS 22 2008 1389 1397
13. DW Cockcroft, MH Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
14. SJ Pocock When to stop a clinical trial BMJ 305 1992 235 240
15. AM Mills, M Nelson, D Jayaweera et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis AIDS 23 2009 1679 1688
16. RH Haubrich, SA Riddler, AG DiRienzo et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment AIDS 23 2009 1109 1118
17. SA Riddler, R Haubrich, AG DiRienzo et al. Class-sparing regimens for initial treatment of HIV-1 infection N Engl J Med 358 2008 2095 2106
18. J Reynes, R Trinh, F Pulido et al. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study AIDS Res Hum Retrovir 29 2013 256 265
19. MJ Kozal, S Lupo, E DeJesus et al. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results HIV Clin Trials 13 2012 119 130
20. JK Rockstroh, E DeJesus, JL Lennox et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK J Acquir Immune Defic Syndr 63 2013 77 85
21. J Reynes, A Lawal, F Pulido et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results HIV Clin Trials 12 2011 255 267
22. B Taiwo, L Zheng, S Gallien et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262) AIDS 25 2011 2113 2122
23. WHO HIV/AIDS Programme Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach 2013 World Health Organization Geneva
24. HF Günthard, JA Aberg, JJ Eron et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA panel JAMA 312 2014 410 425
25. MS Cohen, MK Smith, KE Muessig, TB Hallett, KA Powers, AD Kashuba Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet 382 2013 1515 1524
26. M Kobayashi, T Yoshinaga, T Seki et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor Antimicrob Agents Chemother 55 2011 813 821
27. 3 compared with the general population: evidence from a large European observational cohort collaboration Int J Epidemiol 41 2012 433 445
28. F Raffi, H Jaeger, E Quiros-Roldan for the extended SPRING-2 Study Group Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial Lancet Infect Dis 13 2013 927 935
29. A Zolopa, PE Sax, E DeJesus et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results J Acquir Immune Defic Syndr 63 2013 96 100
30. JB Nachega, JJ Parienti, OA Uthman et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials Clin Infect Dis 58 2014 1297 1307
31. JH Ware, MB Hamel Pragmatic trials - guides to better patient care? N Engl J Med 364 2011 1685 1687
32. L Wittkop, C Smith, Z Fox et al. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field Clin Trials 7 2010 19 35
33. P Flandre Design of HIV noninferiority trials: where are we going? AIDS 27 2013 653 657